New study identifies novel role for PEA-15 protein in cancer growth

A new study from the University of Hawaii Cancer Center reveals that PEA-15, a protein previously shown to slow ovarian tumor growth and metastasis, can alternatively enhance tumor formation in kidney cells carrying a mutation in a cancer-promoting gene called H-Ras.

The H-Ras oncogene is mutated in many human malignancies, and previous reports have shown the ability of H-Ras to contribute to the development, proliferation and metastasis of these tumors. Conversely, PEA-15 had been reported to inhibit tumor and metastasis by opposing H-Ras signals. In ovarian and breast cancer, PEA-15 is proposed to have promising therapeutic potential and in ovarian cancer PEA-15 has shown promise as a marker of prolonged patient survival.

This new study is the first finding of a pro-cancer effect of PEA-15 on proliferation and as such suggests caution in pursuing the use of PEA-15 as an anti-cancer therapeutic. The study results were published online today in the journal Oncogene.

"Our findings reveal a surprising mechanism by which PEA-15 can enhance H-Ras driven transformation of cells, rather than stop it," said Joe W. Ramos, Ph.D., associate professor at the University of Hawaii Cancer Center and co-director of its Cancer Biology Program. "We showed that in a common scenario in which a cell contains a Ras mutation, PEA-15 can accelerate the rate of both in vitro and in vivo," he added.

In contrast to reports suggesting a tumor-suppressor function of PEA-15, Ramos said the discovery confirms that PEA 15 expression can also trigger . "What we now know is that PEA-15 can either enhance or impair the formation of tumors depending on the signaling pathways active in a specific tumor cell."

"As with most cancers, an interplay of factors determines the fate of a patient," noted Florian Sulzmaier, a researcher at the UH Cancer Center and first author of the newly published study. "PEA-15 might still be worth considering for treatment of certain cancers. However, care should be taken in tumor types that carry Ras mutations that could change the outcome of a therapy."

More information: The article, PEA-15 potentiates H-Ras-mediated epithelial cell transformation through phospholipase , appeared in today's online edition of Oncogene.

Journal reference: Oncogene search and more info website

Provided by University of Hawaii Cancer Center

5 /5 (1 vote)

Related Stories

Study finds key protein controls T-cell proliferation

May 04, 2010

New research has identified that a key protein called PEA-15 stops T-cell proliferation by blocking the cell's ability to reproduce. The control of T-cell proliferation is essential in preventing certain blood cancers and ...

High levels of PEA-15 shrink breast cancer tumors

Apr 20, 2009

Overexpression of PEA-15, which binds and drags an oncoprotein out of the cell nucleus where it fuels cancer growth, steeply reduced breast cancer tumors in a preclinical experiment, researchers at The University of Texas ...

Potential new target for cancer found

Jul 15, 2007

By bypassing a well-known gene implicated in almost one-third of all cancers and instead focusing on the protein activated by the gene, Duke University Medical Center researchers believe they may have found a new target for ...

Stress triggers tumor formation, researchers find

Jan 13, 2010

Stress induces signals that cause cells to develop into tumors, Yale researchers have discovered. The research, published online Jan. 13 in the journal Nature, describes a novel way cancer takes hold in the body and sugges ...

Recommended for you

Better classification to improve treatments for breast cancer

3 hours ago

Breast cancer can be classified into ten different subtypes, and scientists have developed a tool to identify which is which. The research, published in the journal Genome Biology, could improve treatments and targeting of tre ...

Risk of diabetes up in hodgkin's lymphoma survivors

5 hours ago

(HealthDay)—Para-aortic radiation correlates with increased diabetes mellitus (DM) risk for Hodgkin's lymphoma (HL) survivors, according to a study published online Aug. 25 in the Journal of Clinical On ...

User comments